Analysts expect Intra-Cellular Therapies Inc (NASDAQ:ITCI) to announce earnings of ($0.95) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Intra-Cellular Therapies’ earnings. The lowest EPS estimate is ($1.26) and the highest is ($0.80). Intra-Cellular Therapies posted earnings of ($0.56) per share in the same quarter last year, which would suggest a negative year over year growth rate of 69.6%. The firm is expected to report its next earnings report on Thursday, March 7th.

On average, analysts expect that Intra-Cellular Therapies will report full-year earnings of ($3.03) per share for the current financial year, with EPS estimates ranging from ($3.38) to ($2.87). For the next financial year, analysts expect that the firm will post earnings of ($3.72) per share, with EPS estimates ranging from ($4.69) to ($3.36). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Intra-Cellular Therapies.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.09.

Several equities analysts have issued reports on ITCI shares. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Wednesday, November 14th. Cantor Fitzgerald set a $32.00 price target on Intra-Cellular Therapies and gave the stock a “buy” rating in a report on Tuesday, October 23rd. BidaskClub raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, September 28th. ValuEngine lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Thursday, November 15th. Finally, Leerink Swann began coverage on Intra-Cellular Therapies in a report on Tuesday, November 13th. They set an “outperform” rating and a $27.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Intra-Cellular Therapies currently has a consensus rating of “Buy” and a consensus price target of $28.25.

Shares of ITCI stock opened at $13.53 on Tuesday. Intra-Cellular Therapies has a 1 year low of $13.29 and a 1 year high of $25.82.

In related news, Director Joel S. Marcus sold 25,000 shares of the firm’s stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $18.24, for a total transaction of $456,000.00. Following the transaction, the director now owns 21,671 shares of the company’s stock, valued at $395,279.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Joel S. Marcus sold 32,000 shares of the firm’s stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $18.17, for a total value of $581,440.00. Following the transaction, the director now directly owns 21,671 shares in the company, valued at approximately $393,762.07. The disclosure for this sale can be found here. Company insiders own 17.40% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Quantbot Technologies LP lifted its position in Intra-Cellular Therapies by 5,520.7% in the third quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,527 shares during the period. Public Employees Retirement Association of Colorado lifted its position in Intra-Cellular Therapies by 127.8% in the third quarter. Public Employees Retirement Association of Colorado now owns 5,687 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 3,190 shares during the period. NumerixS Investment Technologies Inc acquired a new stake in Intra-Cellular Therapies in the second quarter valued at about $167,000. Cubist Systematic Strategies LLC lifted its position in Intra-Cellular Therapies by 53.0% in the second quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 3,339 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its position in Intra-Cellular Therapies by 19.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 20,462 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 3,400 shares during the period. Hedge funds and other institutional investors own 69.53% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

See Also: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Intra-Cellular Therapies (ITCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.